ALX Oncology Holdings Inc. (ALXO) Earnings Call Analysis
NASDAQ · Unknown · Unknown
Earnings Reports
-
ALX Oncology (ALXO) Q1 2026: 100% Response in CD47-High HER2+ Breast Cancer Underscores Biomarker Strategy
June 17, 2026
-
ALXO Q2 2025: CD47 Biomarker Drives 65% ORR in HER2+ Gastric, Reshaping Breast Cancer Strategy
June 16, 2026
-
ALX Oncology (ALXO) Q3 2025: CD47-High Response Rate Hits 65%, Redefining Biomarker-Driven Oncology
June 16, 2026
-
ALX Oncology (ALXO) Q4 2025: $150M Financing Extends Runway, Pivotal Data Milestones Set for 2026–2027
June 15, 2026